Topics:
Breast Cancer • Medical Oncology • MD Anderson • NCI-CCC Tumor Board Question • NCI-CCC Breast Tumor Board Question
How do you approach adjuvant endocrine therapy in a pre-menopausal patient with node negative HR+HER2- breast cancer with a high Oncotype RS who received adjuvant chemotherapy?
What is your specific therapy choice and duration?
Answer from: Medical Oncologist at Academic Institution
The SOFT/TEXT study can be used to answer this question. SOFT was a phase III study in premenopausal women with ER+ disease comparing ovarian function suppression (OFS)+ an aromatase inhibitor (AI) to OFS + tamoxifen vs tamoxifen alone; TEXT compared OFS+AI vs OFS+tamoxifen. The vast majority of wom...
Sign in or Register to read more